Treat comorbid attention-deficit hyperactivity disorder and substance use disorder with both pharmacotherapy and psychotherapy for best results
Year: 2026
Type: article
Abstract: Attention-deficit hyperactivity disorder (ADHD) co-occurring with substance use disorder (SUD) is highly prevalent and is associated with poor prognosis and negative treatment outcomes. Comprehensive management of ADHD-SUD comorbidity involves pharmacotherapy integrated with psychotherapy to enhance treatment retention and success. Psychostimulants are the mainstay of ADHD pharmacotherapy and do not exacerbate SUD symptoms; however, psychostimulants are associated with an inherent risk of misuse, abuse and diversion. Cognitive behavioural therapy is a first-line behavioural intervention that teaches patients harm reduction and coping skills while addressing affective and environmental risks for substance use.
Source: Drugs & Therapy Perspectives
Authors: Kimberley Chen, Connie Kang
Institution: Springer Nature (New Zealand)
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,490
OpenAlex ID: W7166149203